Benzyl Benzoate Liniment Veterinary Grade API, supplied under the model designation BB-VET-LIN-API, is a compendial phenylmethyl benzoate liquid refined for multiple veterinary administration routes: tablets, injections, capsules, powders, granules, premix, and solutions. The substance corresponds to CAS 120-51-4, molecular formula C₁₄H₁₂O₂, and relative molecular mass 212.24 g/mol. At release, it appears as a clear, colorless to faint yellow oily liquid with a refractive index of 1.568–1.570 at 20°C and specific gravity of 1.118–1.122. The ester is practically insoluble in water, miscible with ethanol, isopropanol, acetone, ethyl acetate, medium-chain triglycerides, and most fixed oils. Because the pour point lies near 18°C, bulk storage tanks, transfer lines, and filter housings in production facilities are fitted with low-level heat tracing or jacketed at 20–25°C to prevent partial crystallization in dip pipes and filtration assemblies. The material is manufactured under ICH Q7 for active pharmaceutical ingredients and is accompanied by a batch-specific certificate of analysis covering assay, residual solvents, elemental impurities, microbiological quality, and, where required, bacterial endotoxins. Published data for this specific liniment-grade model across all seven listed dosage forms is limited; however, the compendial identity and manufacturing route are established from public monograph data and API GMP documentation.

What Distinguishes Veterinary Liniment Grade API from Technical, Cosmetic, and Plasticizer-Grade Benzyl Benzoate?

Industrial benzyl benzoate produced for polyvinyl chloride plasticization, dye-carrier, or solvent applications is not processed under pharmaceutical GMP and may retain benzyl chloride, dibenzyl ether, and polycondensation impurities at levels that are unacceptable for injectable or oral veterinary formulations. Cosmetic grade material is often acceptable for fragrance fixation but is not routinely tested for bacterial endotoxins, injection particulate matter, or the full elemental impurity profile expected for an API. The veterinary liniment grade is purified by fractional distillation or thin-film evaporation under reduced pressure after esterification; the distillative step reduces residual benzyl chloride and benzyl alcohol, while nitrogen purging limits peroxide accumulation. Residual benzyl chloride is controlled as a potential genotoxic impurity according to ICH M7(R2) acceptable intake concepts, with batch release limits and confirmatory testing using gas chromatography–mass spectrometry. Unlike technical material, this grade is packaged in nitrogen-blanketed high-density polyethylene drums with induction-sealed closures or 200 kg epoxy-phenolic lined steel drums to limit oxidative yellowing, moisture ingress, and plasticizer cross-contamination.

The liniment-grade designation additionally imposes lower peroxide value and lower water content than technical grades because hydrolytic and oxidative degradation products—benzyl alcohol, benzoic acid, benzaldehyde, and dibenzyl ether—alter formulation pH, accelerate gelatin shell cross-linking, and generate subvisible particles in oil-based injections. A technical-grade lot may exhibit peroxide values above 10 meq/kg and water content above 0.5% w/w; the veterinary API grade is released against tighter in-house limits, typically peroxide value not more than 5 meq/kg and water content not more than 0.2% w/w. The release criteria align with the need for reproducible wetting, emulsification, and compression across multiple downstream platforms.

Specification Profile, Test Methods, and Container-Closure Practices

The following release matrix reflects the compendial and additional provisions applied to benzyl benzoate when designated for multi-route veterinary use. Test values are lot-specific; the acceptance criteria are taken from current USP–NF and Ph. Eur. benzyl benzoate monographs plus internal veterinary requirements.

Container closure systems are qualified for moisture protection and extractables control using USP <671> for non-sterile containers; for injectable-grade lots, elastomeric closures are subject to USP <381> compatibility testing. Residual solvents are controlled according to USP <467> and Ph. Eur. 2.4.24 when benzene, dichloromethane, or methanol are used in the esterification route.

Because benzyl benzoate remains a viscous oily liquid at tableting temperatures, solid-dose manufacturing does not begin with direct compression of the API in neat form. Production-scale tablet lines typically preadsorb the liquid onto porous carriers such as magnesium aluminometasilicate at 20–35% w/w loading, colloidal silicon dioxide at 15–25% w/w, or maltodextrin at 10–20% w/w in a low-shear blender before granulation. On a 600 L high-shear granulator, direct liquid addition to a microcrystalline cellulose–lactose monohydrate blend can produce dough-like agglomerates when water-bearing binders are used; therefore non-aqueous or low-moisture granulation is specified, with impeller speed 120–180 rpm, chopper speed 1,800–2,400 rpm, and product temperature held below 30°C. The granulate is dried in a fluid-bed dryer with inlet air at 40–50°C until residual moisture is below 2.0% w/w, which minimizes hydrolytic release of benzyl alcohol. Compression is performed on a rotary tablet press with precompression force 4–6 kN and main compression force 8–15 kN; target tablet hardness of 50–70 N, friability below 1.0% per USP <1216>, and disintegration below 15 minutes in water at 37°C per USP <701>. Tablets containing significant liquid loadings require aluminum–aluminum blister packaging rather than polyvinyl chloride–polyvinylidene chloride blisters because moisture vapor transmission rates above 0.5 g/m²/day accelerate ester hydrolysis and surface specking.

For capsules, the API is commonly filled as a liquid solution in medium-chain triglycerides or as an adsorbed powder in hard gelatin or hydroxypropyl methylcellulose shells. Fill formulations with water content below 0.5% w/w are required because moisture migration into the shell can alter shell tensile strength and promote capsule splitting. In softgel lines, fill peroxide value is maintained below 5 meq/kg to avoid oxidative cross-linking of the gelatin shell from benzaldehyde and benzoic acid by-products. Powders and granules for oral administration are produced by low-shear tumble blending in 1,000 L bin blenders at 60–70% nominal capacity for 15–20 minutes; stratified sampling after blending routinely achieves relative standard deviation below 3.0% for assays at 10 mg/g to 300 mg/g benzyl benzoate. Feed premixes use a hydrophobic granular carrier such as corncob grits or wheat middlings; the final premix is passed through a 40-mesh screen and is required to meet label claim homogenization under regional veterinary premix GMP.

At low addition levels in premixes, segregation and electrostatic adhesion become limiting. Wall adhesion to stainless steel ribbon blender internals is minimized when the sorbed API is de-lumped through a conical mill equipped with a 0.045 inch screen before blending. Equipment surfaces are earthed, and relative humidity is maintained below 60% RH to prevent moisture-induced stickiness. Production-scale batch records show that premix potency variation increases when liquid benzyl benzoate is sprayed directly onto a moving powder bed without carrier pre-wetting; the preferred method is to pre-blend the liquid with a portion of colloidal silicon dioxide, then introduce the solidified premix into the main blend.

When Benzyl Benzoate Enters Injectable and Solution Manufacturing Lines

Injectable processing places stricter controls on bacterial endotoxin, particulate matter, and oxidative by-products than other routes. An injectable-grade lot is assigned only after bacterial endotoxin testing below 0.5 EU/mg by USP <85> and particulate matter verification consistent with USP <788> after sterilization. Non-aqueous vehicles based on benzyl benzoate are compounded in closed 316L stainless steel vessels purged with filtered nitrogen; contact materials are limited to stainless steel, borosilicate glass, PTFE, and EPDM compliant with USP <381> and <661.1>. Formulations are sterilized by membrane filtration through 0.2 µm polyvinylidene fluoride or nylon capsules and aseptically filled. Terminal steam sterilization at 121°C for 15 minutes may be used for oil-based formulations only when post-sterilization assay and free benzyl alcohol content remain within the registered limit, because steam exposure can hydrolyze a fraction of the ester. Viscosity during filling is typically reduced by warming the bulk solution to 25–30°C; fill-line hold times beyond 24 hours are avoided unless accelerated stability data support longer windows.

Topical liniment solutions are generally prepared as 20–25% w/w benzyl benzoate with ethanol or isopropanol as co-solvent and a nonionic surfactant such as polysorbate 80 at 2–5% w/w. Dispersion is performed in explosion-proof compounding tanks with high-shear rotor–stator mixing at 2,000–3,000 rpm; pH is maintained between 4.0 and 6.0 because alkaline pH above 7.0 accelerates saponification to benzoic acid and benzyl alcohol. Preservative efficacy is tested according to USP <51>; aqueous dilution of the liniment before application is avoided unless the product monograph explicitly allows, because dilution destabilizes the emulsion and may expose the drug to hydrolysis.

Operational boundaries are reinforced by the ester’s susceptibility to alkaline hydrolysis and oxidation. The API is stored in airtight containers protected from light at 15–25°C; repeated opening and exposure to ambient air above 60% RH increases water uptake and peroxide accumulation. The material should not be combined with strong oxidizing agents, strongly alkaline buffers, or untreated copper or zinc alloy fittings, which accelerate oxidative discoloration and formation of benzaldehyde. For solid-dose applications, residual moisture in excipients is controlled to below 2.0% w/w before blending; for injectable and solution applications, water content of the vehicle is held below 0.2% w/w unless the formulation is intentionally emulsified. Incompatibility with certain amines is route-dependent; published data for this specific configuration is limited, but the general behavior of benzyl esters indicates that nucleophilic amine solvents should be avoided in long-term liquid formulations unless forced-degradation studies confirm compatibility.